Drug Profile

Epoetin alfa biosimilar - UBI Pharma

Alternative Names: rhEPO - UBI Pharma; UB-851

Latest Information Update: 21 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UBI Pharma
Class Antianaemics; Recombinant erythropoietins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preregistration Anaemia

Most Recent Events

20 Dec 2023 Preregistration for Anaemia (IV) prior to December 2023 (UBI Pharma pipeline, December 2023)
31 Oct 2021 UBI Pharma completes a phase III trial in Anaemia (IV, Injection) (NCT02708914)
28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Anaemia in Taiwan (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com